CÁCarolina Álvarez-Ortega

Carolina Álvarez-Ortega

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carolina Álvarez-Ortega has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and Economic Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Spanish Mediterranean Region: A Population-Based Study

    by Javier Díaz Carnicero, Inma Saurí-Ferrer, Josep Redon, Jorge Navarro, Gonzalo Fernández, Carlos Hurtado, Karine Ferreira, Carolina Alvarez-Ortega, Antón Gómez, Carlos J. Martos-Rodríguez, et al.

    Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition worldwide, with significant regional variability in prevalence estimates. This study aimed to determine the prevalence, demographic characteristics, and economic burden of MASLD, metabolic dysfunction-associated steatotic liver (MASL), and metabolic dysfunction-associated steatohepatitis (MASH) in the Valencian Community region of Spain. Methods: We conducted a retrospective analysis of electronic medical records from the Valencian public healthcare database of individuals aged over 24 years from 2012 to 2019. Results: Of the 3,411,069 individuals included in the database in 2019, 75,565 were diagnosed with MASLD, 74,065 with MASL, and 1504 with MASH based on the International Classification of Diseases (ICD), corresponding to a prevalence of 2.22%, 2.17%, and 0.04%, respectively. Among individuals with type 2 diabetes mellitus (T2DM) or obesity, the prevalence of MASLD was approximately three times and 2.5 times higher, respectively, compared to the overall population. The prevalence of MASLD, MASL, and MASH increased from 2012 to 2019 in all the populations studied. The highest risk of hospitalization was associated with liver-related causes, followed by all-cause hospitalization. The highest cost per subject in 2019 was observed in individuals with concomitant MASH and T2DM. Conclusions: Our findings indicate a rising prevalence of MASLD, MASL, and MASH, despite their potential underdiagnosis during the study period. The presence of MASLD or MASH was associated with high healthcare costs, particularly in patients with MASH and T2DM. Our results underline the need for more effective strategies to enhance disease awareness and improve resource allocation.


  • Open Access

    440. Steroid Use and Elevated Rates of Coinfections and Mortality in Mild-COVID-19 Patients

    by David E Rebellon-Sanchez, Julio Llanos-Torres, Carolina Álvarez-Ortega, Tania M Guzman-Gonzales, Sarita Rodríguez, Fernando Rosso

    Systemic corticosteroids are used to treat patients with COVID-19. Since the findings of the RECOVERY trial, steroids have been broadly used in critical patients. However, their use in patients with mild disease was unclear and may even be harmful. In the hard times of the pandemic in the absence of widely available vaccines or antivirals agents, hospital overcrowding, patients had to be referred to home care and steroids could be overused. The aim of this study was to explore the relationship between the use of corticosteroids, secondary infections and overall mortality in adults with COVID-19 A prospective observational study was performed in a university hospital in Cali, Colombia. Severity was assessed with NEWS score 2. The study included patients at various levels of severity, including patients admitted to the emergency department, inpatients, and those admitted to the intensive care unit A total of 12,227 patients were treated at our hospital during the first four waves of the pandemic. 54.8% were female, with median age of 45 years (IQR: 31 - 62). 68.5% were classified as mild COVID-19, 8.8% as moderate, and 22.68% as severe. 5.49% of patients were pregnant. Of all patients, 24.30% received corticosteroids upon admission, 11.6% developed secondary infections, and 8.4% died. Mild COVID-19 cases were 1,988 (wave 1), 2,147 (wave 2), 1,628 (wave 3), and 1,608 (wave 4). The proportions of corticosteroid used by waves were 4.3%, 7.18%, 12.5%, and 8.1%, respectively. Corresponding proportions for secondary infections were 2.80%, 5.26%, 6.14%, and 3.8%, while death proportions were 1.7%, 2.5%, 3.2%, and 2.1%. A positive correlation was found between corticosteroid use and secondary infection and mortality rates (Fig. 1). Correlation coefficients were r= 0.9 (p= 0.09) for corticosteroid use and mortality, r= 0.84 (p= 0.15) for corticosteroid use and secondary infection, and r= 0.94 (p= 0.01) for secondary infection and mortality. These correlations were not observed in moderate and severe COVID-19 cases A. Relationship in mild COVID-19 patients. B. Relationship in moderate-to-severe COVID-19 patients Our study shows that the use of corticosteroids in mild cases could correlate with a greater proportion of secondary infections and mortality All Authors: No reported disclosures

  • Open Access

    Effects of a Digital Patient Empowerment and Communication Tool on Metabolic Control in People With Type 2 Diabetes: The DeMpower Multicenter Ambispective Study

    by Domingo Orozco-Beltrán, Cristóbal Morales, Sara Artola-Menéndez, Carlos Brotons, Sara Carrascosa, Cintia González, Óscar Baro, Alberto Aliaga, Karine Ferreira de Campos, María Villarejo, et al.

    Background: Diabetes is a major health care problem, reaching epidemic numbers worldwide. Reducing hemoglobin A1c (HbA1c) levels to recommended targets is associated with a marked decrease in the risk of type 2 diabetes mellitus (T2DM)–related complications. The implementation of new technologies, particularly telemedicine, may be helpful to facilitate self-care and empower people with T2DM, leading to improved metabolic control of the disease. Objective: This study aimed to analyze the effect of a home digital patient empowerment and communication tool (DeMpower App) on metabolic control in people with inadequately controlled T2DM. Methods: The DeMpower study was multicenter with a retrospective (observational: 52 weeks of follow-up) and prospective (interventional: 52 weeks of follow-up) design that included people with T2DM, aged ≥18 and ≤80 years, with HbA1c levels ≥7.5% to ≤9.5%, receiving treatment with noninsulin antihyperglycemic agents, and able to use a smartphone app. Individuals were randomly assigned (2:1) to the DeMpower app–empowered group or control group. We describe the effect of empowerment on the proportion of patients achieving the study glycemic target, defined as HbA1c≤7.5% with a ≥0.5% reduction in HbA1c at week 24. Results: Due to the COVID-19 pandemic, the study was stopped prematurely, and 50 patients (33 in the DeMpower app–empowered group and 17 in the control group) were analyzed. There was a trend toward a higher proportion of patients achieving the study glycemic target (46% vs 18%; P=.07) in the DeMpower app group that was statistically significant when the target was HbA1c≤7.5% (64% vs 24%; P=.02) or HbA1c≤8% (85% vs 53%; P=.02). The mean HbA1c was significantly reduced at week 24 (−0.81, SD 0.89 vs −0.15, SD 1.03; P=.03); trends for improvement in other cardiovascular risk factors, medication adherence, and satisfaction were observed. Conclusions: The results suggest that patient empowerment through home digital tools has a potential effect on metabolic control, which might be even more relevant during the COVID-19 pandemic and in a digital health scenario.